AAM Announces 2019 Board of Directors | Association for Accessible Medicines

AAM Announces 2019 Board of Directors

NEW ORLEANS, LA (February 4, 2019) — The Association for Accessible Medicines (AAM) announced the election of its 2019 Board of Directors and Officers today, at its 2019 Annual Meeting.

Amneal President Robert Stewart will serve as the 2019 AAM Board Chairman. AAM also named Alok Sonig, CEO – US Generics and Global Head – Generics R&D & Biosimilars, Lupin Pharmaceuticals as Vice-Chairman of the Board. Carol Lynch, President, Sandoz US and Head of North America, will serve as Treasurer of AAM.

Generic drugs saved the U.S. health system $265 billion in 2017, according to the Generic Drug Access & Savings in the U.S. report compiled by IQVIA on behalf of AAM.

The 2019 AAM Board of Directors includes:

  • 3M Health Care Business
    Silvia Perez, President & General Manager, Drug Delivery Systems Division
  • Accord Healthcare Inc.
    Gerry Price, President
  • American Regent
    Harsher Singh, Vice President & Chief Commercial Officer
  • Amneal Pharmaceuticals Inc.
    Robert Stewart, President & Chief Executive Officer
  • Apotex Corporation
    Jeff Watson, President & Chief Operating Officer
  • Argentum Pharmaceuticals
    Jeff Gardner, Chief Executive Officer
  • Aurobindo Pharma USA Inc.
    Hunter Murdock, Vice President & General Counsel
  • Bausch Health
    Barbara Purcell, President, Diversified Products
  • Cipla USA
    Nikhil Lalwani, Chief Executive Officer
  • Dr. Reddy's Laboratories Inc.
    Vanessa Brill, Vice President & Regional General Counsel, the Americas
  • Fresenius Kabi USA LLC
    John Ducker, President & Chief Executive Officer
  • Glenmark Generics Inc., USA
    Bob Matsuk, President North America and Global API
  • Hikma Pharmaceuticals
    Brian Hoffmann, President US Generics
  • Lupin Pharmaceuticals
    Alok Sonig, CEO, US Generics and Global Head Generics R&D & Biosimilars
  • Mayne Pharma
    Scott Richards, Chief Executive Officer
  • Mylan, N.V.
    Marcie McClintic Coates, Head of Global Policy
  • Rhodes Pharmaceuticals
    Vince Mancinelli, President
  • Sagent Pharmaceuticals, Inc.
    Peter Kaemmerer, Chief Executive Officer
  • Sandoz Inc., A Novartis Division
    Carol Lynch, President Sandoz US and Head of North America
  • Sun Pharmaceutical Industries, Inc.
    Stephen Manzano, Group Vice President, General Counsel, Secretary and Corporate Compliance
  • Teva Pharmaceuticals USA
    Brendan O'Grady, Executive Vice President, North America
  • Zydus Pharmaceuticals USA
    Joe Renner, Chief Executive Officer & President

A complete list of 2019 AAM Members can be found here.

 

MEDIA CONTACT:
Rachel Schwartz
202.249.7147 (o)
202.251.8881 (c)

 

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.